CZ294909B6 - Buňka imunitního systému s tyrosin-proteinkinázovými chimérickými receptory a léčivo - Google Patents

Buňka imunitního systému s tyrosin-proteinkinázovými chimérickými receptory a léčivo Download PDF

Info

Publication number: CZ294909B6
Authority: CZ; Czechia
Prior art keywords: cell; cells; receptor; protein; kinase
Prior art date: 1995-02-24

Application number

CZ19972601A

Other languages

Czech (cs)

English (en)

Other versions

CZ260197A3 (cs

Inventor

Brian Seed

Charles Romeo

Waldemar Kolanus

Original Assignee

The General Hospital Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-02-24

Filing date

1996-01-24

Publication date

2005-04-13

1996-01-24 Application filed by The General Hospital Corporation filed Critical The General Hospital Corporation

1998-05-13 Publication of CZ260197A3 publication Critical patent/CZ260197A3/cs

2005-04-13 Publication of CZ294909B6 publication Critical patent/CZ294909B6/cs

Links

102000004022 Protein-Tyrosine Kinases Human genes 0.000 title claims abstract description 52
108090000412 Protein-Tyrosine Kinases Proteins 0.000 title claims abstract description 52
108700010039 chimeric receptor Proteins 0.000 title claims abstract description 39
239000003814 drug Substances 0.000 title claims abstract description 6
229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 title claims description 26
230000036039 immunity Effects 0.000 title abstract description 6
108020003175 receptors Proteins 0.000 claims abstract description 79
230000003834 intracellular effect Effects 0.000 claims abstract description 50
230000027455 binding Effects 0.000 claims abstract description 48
206010028980 Neoplasm Diseases 0.000 claims abstract description 21
210000004027 cell Anatomy 0.000 claims description 356
102000005962 receptors Human genes 0.000 claims description 77
101150110875 Syk gene Proteins 0.000 claims description 73
108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 claims description 63
102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 claims description 62
210000000987 immune system Anatomy 0.000 claims description 39
210000001744 T-lymphocyte Anatomy 0.000 claims description 35
239000012678 infectious agent Substances 0.000 claims description 34
241000700605 Viruses Species 0.000 claims description 31
239000000427 antigen Substances 0.000 claims description 31
108091007433 antigens Proteins 0.000 claims description 30
102000036639 antigens Human genes 0.000 claims description 30
230000009089 cytolysis Effects 0.000 claims description 27
210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 26
206010057248 Cell death Diseases 0.000 claims description 23
102000000551 Syk Kinase Human genes 0.000 claims description 19
108010016672 Syk Kinase Proteins 0.000 claims description 19
108020001507 fusion proteins Proteins 0.000 claims description 19
102000037865 fusion proteins Human genes 0.000 claims description 19
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 13
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 13
150000001413 amino acids Chemical class 0.000 claims description 12
230000001363 autoimmune Effects 0.000 claims description 12
239000012528 membrane Substances 0.000 claims description 11
201000011510 cancer Diseases 0.000 claims description 9
230000007246 mechanism Effects 0.000 claims description 7
230000036755 cellular response Effects 0.000 claims description 6
239000003446 ligand Substances 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
230000007812 deficiency Effects 0.000 claims description 5
210000003714 granulocyte Anatomy 0.000 claims description 5
210000002540 macrophage Anatomy 0.000 claims description 5
210000000440 neutrophil Anatomy 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 3
241000894007 species Species 0.000 claims description 3
230000024932 T cell mediated immunity Effects 0.000 claims description 2
102000038012 SFKs Human genes 0.000 claims 2
108091008118 SFKs Proteins 0.000 claims 2
210000003630 histaminocyte Anatomy 0.000 claims 1
235000015097 nutrients Nutrition 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 abstract description 19
239000003795 chemical substances by application Substances 0.000 abstract description 11
230000001524 infective effect Effects 0.000 abstract 4
230000011664 signaling Effects 0.000 abstract 1
108091000080 Phosphotransferase Proteins 0.000 description 86
102000020233 phosphotransferase Human genes 0.000 description 85
108090000623 proteins and genes Proteins 0.000 description 69
230000000694 effects Effects 0.000 description 47
102000004169 proteins and genes Human genes 0.000 description 41
235000018102 proteins Nutrition 0.000 description 39
101100503636 Danio rerio fyna gene Proteins 0.000 description 38
101150018272 FYN gene Proteins 0.000 description 38
108091008874 T cell receptors Proteins 0.000 description 38
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 38
238000001994 activation Methods 0.000 description 32
238000004220 aggregation Methods 0.000 description 31
101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 30
101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 30
102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 30
230000004913 activation Effects 0.000 description 30
238000000034 method Methods 0.000 description 30
230000002776 aggregation Effects 0.000 description 28
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 27
241000725303 Human immunodeficiency virus Species 0.000 description 27
229910052791 calcium Inorganic materials 0.000 description 27
239000011575 calcium Substances 0.000 description 27
230000026731 phosphorylation Effects 0.000 description 27
238000006366 phosphorylation reaction Methods 0.000 description 27
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 26
238000003556 assay Methods 0.000 description 26
230000004044 response Effects 0.000 description 24
108020004414 DNA Proteins 0.000 description 23
239000012634 fragment Substances 0.000 description 21
102000009076 src-Family Kinases Human genes 0.000 description 19
108010087686 src-Family Kinases Proteins 0.000 description 19
102000001253 Protein Kinase Human genes 0.000 description 18
108060006633 protein kinase Proteins 0.000 description 18
230000014509 gene expression Effects 0.000 description 17
230000001461 cytolytic effect Effects 0.000 description 16
239000012636 effector Substances 0.000 description 16
208000015181 infectious disease Diseases 0.000 description 16
239000000126 substance Substances 0.000 description 15
239000002299 complementary DNA Substances 0.000 description 14
150000001875 compounds Chemical class 0.000 description 14
230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 14
206010046865 Vaccinia virus infection Diseases 0.000 description 13
238000000338 in vitro Methods 0.000 description 13
230000001404 mediated effect Effects 0.000 description 13
208000007089 vaccinia Diseases 0.000 description 13
208000030507 AIDS Diseases 0.000 description 12
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 12
230000001413 cellular effect Effects 0.000 description 12
230000006870 function Effects 0.000 description 12
210000004698 lymphocyte Anatomy 0.000 description 12
239000000758 substrate Substances 0.000 description 12
235000002374 tyrosine Nutrition 0.000 description 12
210000004408 hybridoma Anatomy 0.000 description 11
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 11
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 11
210000003719 b-lymphocyte Anatomy 0.000 description 10
239000011651 chromium Substances 0.000 description 10
230000004186 co-expression Effects 0.000 description 10
239000002609 medium Substances 0.000 description 10
239000000523 sample Substances 0.000 description 10
238000011282 treatment Methods 0.000 description 10
102000006306 Antigen Receptors Human genes 0.000 description 9
108010083359 Antigen Receptors Proteins 0.000 description 9
102100027208 T-cell antigen CD7 Human genes 0.000 description 9
235000001014 amino acid Nutrition 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
238000001514 detection method Methods 0.000 description 9
108090000765 processed proteins & peptides Proteins 0.000 description 9
239000013598 vector Substances 0.000 description 9
108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
102100034349 Integrase Human genes 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
108091028043 Nucleic acid sequence Proteins 0.000 description 8
102000004422 Phospholipase C gamma Human genes 0.000 description 8
108010056751 Phospholipase C gamma Proteins 0.000 description 8
241000700618 Vaccinia virus Species 0.000 description 8
229940088598 enzyme Drugs 0.000 description 8
238000003018 immunoassay Methods 0.000 description 8
244000052769 pathogen Species 0.000 description 8
230000001105 regulatory effect Effects 0.000 description 8
241001430294 unidentified retrovirus Species 0.000 description 8
241000894006 Bacteria Species 0.000 description 7
108010041397 CD4 Antigens Proteins 0.000 description 7
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
108091034117 Oligonucleotide Proteins 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
210000000170 cell membrane Anatomy 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
230000028993 immune response Effects 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
239000000047 product Substances 0.000 description 7
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 6
208000031886 HIV Infections Diseases 0.000 description 6
230000006044 T cell activation Effects 0.000 description 6
230000000890 antigenic effect Effects 0.000 description 6
238000013459 approach Methods 0.000 description 6
229910001424 calcium ion Inorganic materials 0.000 description 6
230000001472 cytotoxic effect Effects 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
230000004927 fusion Effects 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
239000012133 immunoprecipitate Substances 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
238000011534 incubation Methods 0.000 description 6
230000035772 mutation Effects 0.000 description 6
230000001717 pathogenic effect Effects 0.000 description 6
230000019491 signal transduction Effects 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
101150028321 Lck gene Proteins 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
102000014400 SH2 domains Human genes 0.000 description 5
108050003452 SH2 domains Proteins 0.000 description 5
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 5
125000003275 alpha amino acid group Chemical group 0.000 description 5
239000000872 buffer Substances 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
231100000433 cytotoxic Toxicity 0.000 description 5
230000006378 damage Effects 0.000 description 5
PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 5
230000002458 infectious effect Effects 0.000 description 5
230000003993 interaction Effects 0.000 description 5
238000000021 kinase assay Methods 0.000 description 5
238000002372 labelling Methods 0.000 description 5
229910052751 metal Inorganic materials 0.000 description 5
239000002184 metal Substances 0.000 description 5
239000013642 negative control Substances 0.000 description 5
150000007523 nucleic acids Chemical group 0.000 description 5
DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 5
238000010561 standard procedure Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000035897 transcription Effects 0.000 description 5
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 4
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 4
108091026890 Coding region Proteins 0.000 description 4
101710091045 Envelope protein Proteins 0.000 description 4
241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
241000713340 Human immunodeficiency virus 2 Species 0.000 description 4
108010073816 IgE Receptors Proteins 0.000 description 4
102000009438 IgE Receptors Human genes 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 4
239000000020 Nitrocellulose Substances 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
108010029485 Protein Isoforms Proteins 0.000 description 4
102000001708 Protein Isoforms Human genes 0.000 description 4
101710188315 Protein X Proteins 0.000 description 4
-1 acridine ester Chemical class 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
229910052804 chromium Inorganic materials 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
230000002950 deficient Effects 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
238000000684 flow cytometry Methods 0.000 description 4
210000002443 helper t lymphocyte Anatomy 0.000 description 4
108010075597 immunoglobulin M receptor Proteins 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
210000000822 natural killer cell Anatomy 0.000 description 4
229920001220 nitrocellulos Polymers 0.000 description 4
244000045947 parasite Species 0.000 description 4
229960003330 pentetic acid Drugs 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
230000002103 transcriptional effect Effects 0.000 description 4
230000001960 triggered effect Effects 0.000 description 4
241000283707 Capra Species 0.000 description 3
102000000844 Cell Surface Receptors Human genes 0.000 description 3
108010001857 Cell Surface Receptors Proteins 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
241000233866 Fungi Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
241001529936 Murinae Species 0.000 description 3
108010004729 Phycoerythrin Proteins 0.000 description 3
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
108091005682 Receptor kinases Proteins 0.000 description 3
241000272534 Struthio camelus Species 0.000 description 3
101800001690 Transmembrane protein gp41 Proteins 0.000 description 3
INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000010276 construction Methods 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
239000013613 expression plasmid Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000001114 immunoprecipitation Methods 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
230000006698 induction Effects 0.000 description 3
239000006166 lysate Substances 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
230000002018 overexpression Effects 0.000 description 3
230000037361 pathway Effects 0.000 description 3
239000013641 positive control Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
230000000284 resting effect Effects 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
230000001629 suppression Effects 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
238000001890 transfection Methods 0.000 description 3
230000014616 translation Effects 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 3
108010012919 B-Cell Antigen Receptors Proteins 0.000 description 2
102000019260 B-Cell Antigen Receptors Human genes 0.000 description 2
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 2
102100032912 CD44 antigen Human genes 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
108010009685 Cholinergic Receptors Proteins 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
101710121417 Envelope glycoprotein Proteins 0.000 description 2
108010087819 Fc receptors Proteins 0.000 description 2
102000009109 Fc receptors Human genes 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
208000037357 HIV infectious disease Diseases 0.000 description 2
108010014597 HLA-B44 Antigen Proteins 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
108010073807 IgG Receptors Proteins 0.000 description 2
102000009490 IgG Receptors Human genes 0.000 description 2
206010061598 Immunodeficiency Diseases 0.000 description 2
208000029462 Immunodeficiency disease Diseases 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102000004195 Isomerases Human genes 0.000 description 2
108090000769 Isomerases Proteins 0.000 description 2
241000713666 Lentivirus Species 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
108010089430 Phosphoproteins Proteins 0.000 description 2
102000007982 Phosphoproteins Human genes 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
102100025237 T-cell surface antigen CD2 Human genes 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
102000014384 Type C Phospholipases Human genes 0.000 description 2
108010079194 Type C Phospholipases Proteins 0.000 description 2
108010067390 Viral Proteins Proteins 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
102000034337 acetylcholine receptors Human genes 0.000 description 2
230000003321 amplification Effects 0.000 description 2
238000011394 anticancer treatment Methods 0.000 description 2
230000035578 autophosphorylation Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
230000007969 cellular immunity Effects 0.000 description 2
ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
239000003599 detergent Substances 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
239000000539 dimer Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
210000003958 hematopoietic stem cell Anatomy 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000007813 immunodeficiency Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
239000012160 loading buffer Substances 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
206010028417 myasthenia gravis Diseases 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
230000009696 proliferative response Effects 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
210000003370 receptor cell Anatomy 0.000 description 2
108010043277 recombinant soluble CD4 Proteins 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000000527 sonication Methods 0.000 description 2
238000002798 spectrophotometry method Methods 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
210000001541 thymus gland Anatomy 0.000 description 2
230000009258 tissue cross reactivity Effects 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 description 1
IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
239000007991 ACES buffer Substances 0.000 description 1
239000007988 ADA buffer Substances 0.000 description 1
102000012440 Acetylcholinesterase Human genes 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
208000016557 Acute basophilic leukemia Diseases 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102100023635 Alpha-fetoprotein Human genes 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
240000003291 Armoracia rusticana Species 0.000 description 1
235000011330 Armoracia rusticana Nutrition 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108091008875 B cell receptors Proteins 0.000 description 1
102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 1
230000003844 B-cell-activation Effects 0.000 description 1
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
108700031361 Brachyury Proteins 0.000 description 1
102000049320 CD36 Human genes 0.000 description 1
108010045374 CD36 Antigens Proteins 0.000 description 1
108010063916 CD40 Antigens Proteins 0.000 description 1
101150013553 CD40 gene Proteins 0.000 description 1
108010032795 CD8 receptor Proteins 0.000 description 1
101150012716 CDK1 gene Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
102100035882 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
102100032768 Complement receptor type 2 Human genes 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
101000606500 Gallus gallus Inactive tyrosine-protein kinase 7 Proteins 0.000 description 1
101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
102100022624 Glucoamylase Human genes 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
239000007996 HEPPS buffer Substances 0.000 description 1
241000251188 Holocephali Species 0.000 description 1
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 1
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
102000036243 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Human genes 0.000 description 1
108010002481 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Proteins 0.000 description 1
102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
239000007993 MOPS buffer Substances 0.000 description 1
101710141347 Major envelope glycoprotein Proteins 0.000 description 1
102000013460 Malate Dehydrogenase Human genes 0.000 description 1
108010026217 Malate Dehydrogenase Proteins 0.000 description 1
108010059724 Micrococcal Nuclease Proteins 0.000 description 1
101100503641 Mus musculus Fyn gene Proteins 0.000 description 1
DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 description 1
BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
239000007990 PIPES buffer Substances 0.000 description 1
206010033661 Pancytopenia Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
102000015439 Phospholipases Human genes 0.000 description 1
108010064785 Phospholipases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
241000233872 Pneumocystis carinii Species 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
241000288906 Primates Species 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
108700020978 Proto-Oncogene Proteins 0.000 description 1
102000052575 Proto-Oncogene Human genes 0.000 description 1
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
102000000395 SH3 domains Human genes 0.000 description 1
108050008861 SH3 domains Proteins 0.000 description 1
108010008038 Synthetic Vaccines Proteins 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
108700026226 TATA Box Proteins 0.000 description 1
239000007994 TES buffer Substances 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
229940022698 acetylcholinesterase Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000001251 acridines Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000004931 aggregating effect Effects 0.000 description 1
230000008841 allosteric interaction Effects 0.000 description 1
108010026331 alpha-Fetoproteins Proteins 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000019552 anatomical structure morphogenesis Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
SFZBBUSDVJSDGR-XWFYHZIMSA-N beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@H]2[C@H]([C@@H](CO)O[C@@H](O)[C@@H]2O)O)[C@@H]1NC(C)=O SFZBBUSDVJSDGR-XWFYHZIMSA-N 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
238000005415 bioluminescence Methods 0.000 description 1
230000029918 bioluminescence Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
230000001201 calcium accumulation Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
230000034303 cell budding Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000009172 cell transfer therapy Methods 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
239000002131 composite material Substances 0.000 description 1
238000007596 consolidation process Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000011266 cytolytic assay Methods 0.000 description 1
238000004163 cytometry Methods 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
208000024389 cytopenia Diseases 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
230000002498 deadly effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
229950006137 dexfosfoserine Drugs 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
210000003162 effector t lymphocyte Anatomy 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
239000000284 extract Substances 0.000 description 1
ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
238000005558 fluorometry Methods 0.000 description 1
230000004907 flux Effects 0.000 description 1
230000037433 frameshift Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
101150106093 gpt gene Proteins 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
210000000777 hematopoietic system Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
210000004754 hybrid cell Anatomy 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000005934 immune activation Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
102000027596 immune receptors Human genes 0.000 description 1
108091008915 immune receptors Proteins 0.000 description 1
230000000899 immune system response Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000007326 intracellular aggregation Effects 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
238000003674 kinase activity assay Methods 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
229910052746 lanthanum Inorganic materials 0.000 description 1
FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
230000027928 long-term synaptic potentiation Effects 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
210000004882 non-tumor cell Anatomy 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
238000006384 oligomerization reaction Methods 0.000 description 1
230000003606 oligomerizing effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000010355 oscillation Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
210000004214 philadelphia chromosome Anatomy 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
108091005981 phosphorylated proteins Proteins 0.000 description 1
238000003566 phosphorylation assay Methods 0.000 description 1
BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical group OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000004537 potential cytotoxicity Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
229940124551 recombinant vaccine Drugs 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000008521 reorganization Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
208000011581 secondary neoplasm Diseases 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
FLNVBBPBGKOJHN-KKAOYSRWSA-N sivmac Chemical compound O=C([C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O FLNVBBPBGKOJHN-KKAOYSRWSA-N 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
PXLIDIMHPNPGMH-UHFFFAOYSA-N sodium chromate Chemical compound [Na+].[Na+].[O-][Cr]([O-])(=O)=O PXLIDIMHPNPGMH-UHFFFAOYSA-N 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
230000008685 targeting Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000002463 transducing effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
239000013638 trimer Substances 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
150000003668 tyrosines Chemical class 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
230000007482 viral spreading Effects 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
108010015889 zeta receptor Proteins 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Cell Biology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Developmental Biology & Embryology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Hematology (AREA)
General Engineering & Computer Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CZ19972601A 1995-02-24 1996-01-24 Buňka imunitního systému s tyrosin-proteinkinázovými chimérickými receptory a léčivo CZ294909B6 (cs)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/394,177 US5912170A (en)	1991-03-07	1995-02-24	Redirection of cellular immunity by protein-tyrosine kinase chimeras

Publications (2)

Publication Number	Publication Date
CZ260197A3 CZ260197A3 (cs)	1998-05-13
CZ294909B6 true CZ294909B6 (cs)	2005-04-13

Family

ID=23557887

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CZ19972601A CZ294909B6 (cs)	1995-02-24	1996-01-24	Buňka imunitního systému s tyrosin-proteinkinázovými chimérickými receptory a léčivo

Country Status (19)

Country	Link
US (3)	US5912170A (2)
EP (1)	EP0812352B1 (2)
JP (1)	JP4170389B2 (2)
KR (1)	KR100454396B1 (2)
AT (1)	ATE323755T1 (2)
AU (1)	AU703125C (2)
CA (1)	CA2209301C (2)
CZ (1)	CZ294909B6 (2)
DE (1)	DE69636053T2 (2)
DK (1)	DK0812352T3 (2)
ES (1)	ES2258772T3 (2)
FI (1)	FI121012B (2)
HU (1)	HU225689B1 (2)
NO (1)	NO321459B1 (2)
NZ (2)	NZ501340A (2)
PT (1)	PT812352E (2)
RU (1)	RU2225870C2 (2)
WO (1)	WO1996026265A1 (2)
ZA (1)	ZA961476B (2)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5851828A (en)	1991-03-07	1998-12-22	The General Hospital Corporation	Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5912170A (en)	1991-03-07	1999-06-15	The General Hospital Corporation	Redirection of cellular immunity by protein-tyrosine kinase chimeras
US7049136B2 (en)	1991-03-07	2006-05-23	The General Hospital Corporation	Redirection of cellular immunity by receptor chimeras
US6753162B1 (en)	1991-03-07	2004-06-22	The General Hospital Corporation	Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US6004811A (en)	1991-03-07	1999-12-21	The Massachussetts General Hospital	Redirection of cellular immunity by protein tyrosine kinase chimeras
AU708339B2 (en) *	1995-02-24	1999-08-05	General Hospital Corporation, The	Redirection of cellular immunity by receptor chimeras
GB9526131D0 (en) *	1995-12-21	1996-02-21	Celltech Therapeutics Ltd	Recombinant chimeric receptors
DK1905457T3 (da) *	1999-12-22	2012-05-29	Scripps Research Inst	Farmaceutiske sammensætninger omfattende Src og/eller Yes samt anvendelse deraf
IL137419A0 (en) *	2000-07-20	2001-07-24	Yissum Res Dev Co	Nk cells activating receptors and their therapeutic and diagnostic uses
US9045739B2 (en) *	2004-01-16	2015-06-02	Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V.	Immunokinases
US8883507B2 (en)	2005-10-18	2014-11-11	The Regents Of The University Of Colorado	Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
EP1800695A1 (en) *	2005-12-21	2007-06-27	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Immuno-RNA-constructs
WO2008017517A1 (en)	2006-08-11	2008-02-14	Life Sciences Research Partners Vzw	Immunogenic peptides and their use in immune disorders
CN101828113B (zh) *	2007-07-25	2014-04-16	德国弗劳恩霍夫协会债权安格万特学术研究所	自结合重组抗体融合蛋白
US8450053B2 (en) *	2007-09-11	2013-05-28	University Of Maryland, Baltimore	ZAP-70 as predictor and modulator of effector function of T cells
SG10201803982TA (en)	2008-05-16	2018-07-30	Taiga Biotechnologies Inc	Antibodies and processes for preparing the same
US8784825B2 (en)	2008-08-28	2014-07-22	Taiga Biotechnologies, Inc.	Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
WO2011119920A2 (en)	2010-03-25	2011-09-29	Oregon Health & Science University	Cmv glycoproteins and recombinant vectors
ES2667425T3 (es)	2011-06-10	2018-05-10	Oregon Health & Science University	Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en)	2011-09-12	2013-03-28	International Aids Vaccine Initiative	Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en)	2011-10-27	2013-05-01	Christopher L. Parks	Viral particles derived from an enveloped virus
GB201201511D0 (en)	2012-01-30	2012-03-14	Univ Leuven Kath	Modified epitopes for boosting CD4+ T-cell responses
EP2679596B1 (en)	2012-06-27	2017-04-12	International Aids Vaccine Initiative	HIV-1 env glycoprotein variant
JP6285930B2 (ja)	2012-07-20	2018-02-28	タイガバイオテクノロジーズ，インク．	造血コンパートメントの再構築及び自家再構築の増進
EP2934532B1 (en)	2012-12-20	2019-10-23	Purdue Research Foundation	Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US10272115B2 (en)	2013-03-11	2019-04-30	Taiga Biotechnologies, Inc.	Production and use of red blood cells
US20150065381A1 (en)	2013-09-05	2015-03-05	International Aids Vaccine Initiative	Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en)	2013-10-07	2017-05-31	International Aids Vaccine Initiative	Soluble hiv-1 envelope glycoprotein trimers
WO2015077717A1 (en)	2013-11-25	2015-05-28	The Broad Institute Inc.	Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en)	2013-12-05	2015-06-11	The Broad Institute Inc.	Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja)	2013-12-20	2022-04-26	ザ・ブロード・インスティテュート・インコーポレイテッド	ネオ抗原ワクチンによる併用療法
ES2688035T3 (es)	2014-08-29	2018-10-30	Gemoab Monoclonals Gmbh	Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
US10975442B2 (en)	2014-12-19	2021-04-13	Massachusetts Institute Of Technology	Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en)	2014-12-19	2020-11-25	The Broad Institute, Inc.	Methods for profiling the t-cell- receptor repertoire
US10174292B2 (en)	2015-03-20	2019-01-08	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en)	2015-03-23	2016-09-28	International Aids Vaccine Initiative	Soluble hiv-1 envelope glycoprotein trimers
JP6913032B2 (ja)	2015-05-20	2021-08-04	ザ・ブロード・インスティテュート・インコーポレイテッド	共通ネオ抗原
AU2016279062A1 (en)	2015-06-18	2019-03-28	Omar O. Abudayyeh	Novel CRISPR enzymes and systems
US12241053B2 (en)	2015-10-09	2025-03-04	The Brigham And Women's Hospital, Inc.	Modulation of novel immune checkpoint targets
WO2017075465A1 (en)	2015-10-28	2017-05-04	The Broad Institute Inc.	Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en)	2015-10-28	2017-05-04	The Broad Institute Inc.	Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075478A2 (en)	2015-10-28	2017-05-04	The Broad Institute Inc.	Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
CA3005878A1 (en)	2015-11-19	2017-05-26	The Brigham And Women's Hospital, Inc.	Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
CA3019835A1 (en)	2016-04-08	2017-10-12	Purdue Research Foundation	Methods and compositions for car t cell therapy
AU2017254477A1 (en)	2016-04-18	2018-11-01	Jennifer G. ABELIN	Improved HLA epitope prediction
US11630103B2 (en)	2016-08-17	2023-04-18	The Broad Institute, Inc.	Product and methods useful for modulating and evaluating immune responses
US20190262399A1 (en)	2016-09-07	2019-08-29	The Broad Institute, Inc.	Compositions and methods for evaluating and modulating immune responses
US12499971B2 (en)	2016-09-28	2025-12-16	The Broad Institute, Inc.	Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
US12447213B2 (en)	2016-10-07	2025-10-21	The Broad Institute, Inc.	Modulation of novel immune checkpoint targets
WO2018089386A1 (en)	2016-11-11	2018-05-17	The Broad Institute, Inc.	Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
US10583156B2 (en)	2016-12-02	2020-03-10	Taiga Biotechnologies, Inc.	Nanoparticle formulations
EP3574116A1 (en)	2017-01-24	2019-12-04	The Broad Institute, Inc.	Compositions and methods for detecting a mutant variant of a polynucleotide
AU2018219226B2 (en)	2017-02-07	2024-12-19	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN110809716B (zh)	2017-02-12	2023-07-07	百欧恩泰美国公司	基于hla的方法和组合物及其用途
CN110582288B (zh)	2017-02-28	2024-09-20	恩多塞特公司	用于car t细胞疗法的组合物和方法
US11963966B2 (en)	2017-03-31	2024-04-23	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating ovarian tumors
EP3606518A4 (en)	2017-04-01	2021-04-07	The Broad Institute, Inc.	METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
US12590288B2 (en)	2017-04-12	2026-03-31	The Broad Institute, Inc.	Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response
US20200071773A1 (en)	2017-04-12	2020-03-05	Massachusetts Eye And Ear Infirmary	Tumor signature for metastasis, compositions of matter methods of use thereof
US20210293783A1 (en)	2017-04-18	2021-09-23	The General Hospital Corporation	Compositions for detecting secretion and methods of use
JP2020517259A (ja)	2017-04-19	2020-06-18	ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム	操作された抗原受容体を発現する免疫細胞
US12226479B2 (en)	2017-05-11	2025-02-18	The General Hospital Corporation	Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
EP3625342B1 (en)	2017-05-18	2022-08-24	The Broad Institute, Inc.	Systems, methods, and compositions for targeted nucleic acid editing
EP3638218A4 (en)	2017-06-14	2021-06-09	The Broad Institute, Inc.	COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
WO2019014581A1 (en)	2017-07-14	2019-01-17	The Broad Institute, Inc.	METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
EP4026554A1 (en)	2017-08-03	2022-07-13	Taiga Biotechnologies, Inc.	Methods and compositions for the treatment of melanoma
US10149898B2 (en)	2017-08-03	2018-12-11	Taiga Biotechnologies, Inc.	Methods and compositions for the treatment of melanoma
KR102338449B1 (ko)	2017-09-21	2021-12-10	더 브로드 인스티튜트, 인코퍼레이티드	표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물
WO2019070755A1 (en)	2017-10-02	2019-04-11	The Broad Institute, Inc.	METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
US11732257B2 (en)	2017-10-23	2023-08-22	Massachusetts Institute Of Technology	Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
WO2019094983A1 (en)	2017-11-13	2019-05-16	The Broad Institute, Inc.	Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
US12171783B2 (en)	2017-11-13	2024-12-24	The Broad Institute, Inc.	Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
US11994512B2 (en)	2018-01-04	2024-05-28	Massachusetts Institute Of Technology	Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
WO2019144095A1 (en)	2018-01-22	2019-07-25	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Methods of use for car t cells
AU2019218729B2 (en)	2018-02-06	2025-12-04	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
WO2019165121A1 (en)	2018-02-21	2019-08-29	Board Of Regents, The University Of Texas System	Methods for activation and expansion of natural killer cells and uses therof
JP7568224B2 (ja)	2018-02-23	2024-10-16	エンドサイト・インコーポレイテッド	Ｃａｒｔ細胞療法のための配列決定法
KR20200130709A (ko)	2018-03-06	2020-11-19	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	전립선-특이 막 항원 car 및 이의 사용 방법
US11957695B2 (en)	2018-04-26	2024-04-16	The Broad Institute, Inc.	Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019232542A2 (en)	2018-06-01	2019-12-05	Massachusetts Institute Of Technology	Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
WO2019241273A1 (en)	2018-06-11	2019-12-19	The Broad Institute, Inc.	Lineage tracing using mitochondrial genome mutations and single cell genomics
US12036240B2 (en)	2018-06-14	2024-07-16	The Broad Institute, Inc.	Compositions and methods targeting complement component 3 for inhibiting tumor growth
US12391685B2 (en)	2018-08-20	2025-08-19	The Broad Institute, Inc.	Inhibitors of RNA-guided nuclease target binding and uses thereof
WO2020041384A1 (en)	2018-08-20	2020-02-27	The Broad Institute, Inc.	3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
WO2020041387A1 (en)	2018-08-20	2020-02-27	The Brigham And Women's Hospital, Inc.	Degradation domain modifications for spatio-temporal control of rna-guided nucleases
US20210382068A1 (en)	2018-10-02	2021-12-09	Dana-Farber Cancer Institute, Inc.	Hla single allele lines
WO2020081730A2 (en)	2018-10-16	2020-04-23	Massachusetts Institute Of Technology	Methods and compositions for modulating microenvironment
WO2020092455A2 (en)	2018-10-29	2020-05-07	The Broad Institute, Inc.	Car t cell transcriptional atlas
WO2020092057A1 (en)	2018-10-30	2020-05-07	Yale University	Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
WO2020131586A2 (en)	2018-12-17	2020-06-25	The Broad Institute, Inc.	Methods for identifying neoantigens
CA3124457A1 (en)	2018-12-21	2020-06-25	Biontech Us Inc.	Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
US11739156B2 (en)	2019-01-06	2023-08-29	The Broad Institute, Inc. Massachusetts Institute of Technology	Methods and compositions for overcoming immunosuppression
WO2020186101A1 (en)	2019-03-12	2020-09-17	The Broad Institute, Inc.	Detection means, compositions and methods for modulating synovial sarcoma cells
EP3942023A1 (en)	2019-03-18	2022-01-26	The Broad Institute, Inc.	Compositions and methods for modulating metabolic regulators of t cell pathogenicity
EP3952909A4 (en)	2019-04-08	2023-06-07	Taiga Biotechnologies, Inc.	COMPOSITIONS AND METHODS FOR CRYOPRESERVING IMMUNE CELLS
SG11202112529WA (en)	2019-05-14	2021-12-30	Taiga Biotechnologies Inc	Compositions and methods for treating t cell exhaustion
US20220235340A1 (en)	2019-05-20	2022-07-28	The Broad Institute, Inc.	Novel crispr-cas systems and uses thereof
WO2020243371A1 (en)	2019-05-28	2020-12-03	Massachusetts Institute Of Technology	Methods and compositions for modulating immune responses
US20220282333A1 (en)	2019-08-13	2022-09-08	The General Hospital Corporation	Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en)	2019-08-16	2025-09-23	The Broad Institute, Inc.	Methods for predicting outcomes and treating colorectal cancer using a cell atlas
US20220298501A1 (en)	2019-08-30	2022-09-22	The Broad Institute, Inc.	Crispr-associated mu transposase systems
US20220401537A1 (en) *	2019-09-16	2022-12-22	Fred Hutchinson Cancer Research Center	Chimeric receptor proteins and uses thereof
US12297426B2 (en)	2019-10-01	2025-05-13	The Broad Institute, Inc.	DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en)	2019-10-02	2025-08-19	The General Hospital Corporation	Method for predicting HLA-binding peptides using protein structural features
US12195725B2 (en)	2019-10-03	2025-01-14	Dana-Farber Cancer Institute, Inc.	Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en)	2019-10-03	2024-05-14	Dana-Farber Cancer Institute, Inc.	Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en)	2019-10-07	2023-10-24	The Broad Institute, Inc.	Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11844800B2 (en)	2019-10-30	2023-12-19	Massachusetts Institute Of Technology	Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
US12195723B2 (en)	2019-11-08	2025-01-14	The Broad Institute, Inc.	Engineered antigen presenting cells and uses thereof
US12165747B2 (en)	2020-01-23	2024-12-10	The Broad Institute, Inc.	Molecular spatial mapping of metastatic tumor microenvironment
IL295063A (en)	2020-02-04	2022-09-01	Seattle Childrens Hospital Dba Seattle Childrens Res Inst	Chimeric antigen receptors (car) against dinitrophenol
CA3188988A1 (en)	2020-08-13	2022-02-17	Sidi CHEN	Compositions and methods for engineering and selection of car t cells with desired phenotypes
WO2023173137A1 (en)	2022-03-11	2023-09-14	Yale University	Compositions and methods for efficient and stable genetic modification of eukaryotic cells
US20250161360A1 (en)	2022-05-10	2025-05-22	Yale University	Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
EP4598949A1 (en)	2022-10-07	2025-08-13	The General Hospital Corporation	Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
WO2024124044A1 (en)	2022-12-07	2024-06-13	The Brigham And Women’S Hospital, Inc.	Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024155821A1 (en)	2023-01-18	2024-07-25	Yale University	Chimeric antigen receptors (car) with intrinsically disordered regions and methods of use thereof
WO2024192141A1 (en)	2023-03-13	2024-09-19	Dana-Farber Cancer Institute, Inc.	Treatment of cancers having a drug-resistant mesenchymal cell state
WO2024226838A2 (en)	2023-04-25	2024-10-31	The Brigham And Women's Hospital, Inc.	Treatment of autoimmune diseases having a pathogenic t cell state
WO2024226829A2 (en)	2023-04-26	2024-10-31	Yale University	Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
WO2024238656A1 (en)	2023-05-15	2024-11-21	Yale Univeristy	Chimeric antigen receptor compositions, car-mast cells formed therefrom, and methods of use thereof
US12531162B1 (en) *	2023-05-31	2026-01-20	Northeastern University	Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
WO2025059533A1 (en)	2023-09-13	2025-03-20	The Broad Institute, Inc.	Crispr enzymes and systems
WO2025097055A2 (en)	2023-11-02	2025-05-08	The Broad Institute, Inc.	Compositions and methods of use of t cells in immunotherapy
US12562256B2 (en) *	2023-11-07	2026-02-24	New York University	Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
WO2025117544A1 (en)	2023-11-29	2025-06-05	The Broad Institute, Inc.	Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4873190A (en) *	1984-06-13	1989-10-10	Massachusetts Institute Of Technology	Heterodimeric T lymphocyte receptor
GB8422238D0 (en) *	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US4690915A (en) *	1985-08-08	1987-09-01	The United States Of America As Represented By The Department Of Health And Human Services	Adoptive immunotherapy as a treatment modality in humans
EP0281604B1 (en) *	1986-09-02	1993-03-31	Enzon Labs Inc.	Single polypeptide chain binding molecules
US4946778A (en) *	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US4808151A (en) *	1987-04-27	1989-02-28	E. I. Du Pont De Nemours And Company	Simplified method for the preparation of human lymphokine activated killer cells
US5091513A (en) *	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
JPS6463394A (en) *	1987-09-04	1989-03-09	Kyowa Hakko Kogyo Kk	Novel chimera polypeptide
NZ226414A (en) *	1987-10-02	1992-07-28	Genentech Inc	Cd4 peptide adhesion variants and their preparation and use
US5336603A (en) *	1987-10-02	1994-08-09	Genentech, Inc.	CD4 adheson variants
IL86278A (en) *	1988-05-04	2003-06-24	Yeda Res & Dev	Endowing cells with antibody specificity using chimeric t cell receptor
CA2000878C (en) *	1988-10-18	1999-06-29	Jean-Pierre Kinet	Cdnas coding for the subunit of the high-affinity receptor for immunoglobulin e
US5225538A (en) *	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
FR2644463A1 (2) *	1989-03-17	1990-09-21	Pasteur Institut
EP0394827A1 (en) *	1989-04-26	1990-10-31	F. Hoffmann-La Roche Ag	Chimaeric CD4-immunoglobulin polypeptides
WO1991010736A2 (en) *	1990-01-19	1991-07-25	Dana Farber Cancer Institute	CLONING AND CHARACTERIZATION OF THE CD3θ SUBUNIT
ATE145428T1 (de) *	1990-12-14	1996-12-15	Cell Genesys Inc	Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US6004811A (en) *	1991-03-07	1999-12-21	The Massachussetts General Hospital	Redirection of cellular immunity by protein tyrosine kinase chimeras
US5851828A (en)	1991-03-07	1998-12-22	The General Hospital Corporation	Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
IE920716A1 (en) *	1991-03-07	1992-09-09	Gen Hospital Corp	Redirection of cellular immunity by receptor chimeras
US5912170A (en)	1991-03-07	1999-06-15	The General Hospital Corporation	Redirection of cellular immunity by protein-tyrosine kinase chimeras
WO1993019163A1 (en) *	1992-03-18	1993-09-30	Yeda Research And Development Co, Ltd.	Chimeric receptor genes and cells transformed therewith
JP3588115B2 (ja) *	1993-07-16	2004-11-10	ザジェネラルホスピタルコーポレーション	レセプターキメラによる細胞性免疫の回復
US5439819A (en) *	1993-08-27	1995-08-08	The Regents Of The University Of California	Chimeric protein tyrosine kinases
US5712149A (en) *	1995-02-03	1998-01-27	Cell Genesys, Inc.	Chimeric receptor molecules for delivery of co-stimulatory signals
JP3782521B2 (ja)	1996-08-23	2006-06-07	富士通コンポーネント株式会社	押釦構造およびキーボード

1995
- 1995-02-24 US US08/394,177 patent/US5912170A/en not_active Expired - Lifetime
1996
- 1996-01-24 DE DE69636053T patent/DE69636053T2/de not_active Expired - Lifetime
- 1996-01-24 AT AT96903666T patent/ATE323755T1/de active
- 1996-01-24 WO PCT/US1996/001001 patent/WO1996026265A1/en not_active Ceased
- 1996-01-24 RU RU97115895/13A patent/RU2225870C2/ru active
- 1996-01-24 NZ NZ50134096A patent/NZ501340A/xx not_active IP Right Cessation
- 1996-01-24 KR KR1019970705851A patent/KR100454396B1/ko not_active Expired - Lifetime
- 1996-01-24 JP JP52568396A patent/JP4170389B2/ja not_active Expired - Lifetime
- 1996-01-24 NZ NZ302090A patent/NZ302090A/xx not_active IP Right Cessation
- 1996-01-24 EP EP96903666A patent/EP0812352B1/en not_active Expired - Lifetime
- 1996-01-24 DK DK96903666T patent/DK0812352T3/da active
- 1996-01-24 CZ CZ19972601A patent/CZ294909B6/cs not_active IP Right Cessation
- 1996-01-24 AU AU47675/96A patent/AU703125C/en not_active Expired
- 1996-01-24 PT PT96903666T patent/PT812352E/pt unknown
- 1996-01-24 ES ES96903666T patent/ES2258772T3/es not_active Expired - Lifetime
- 1996-01-24 HU HU9800459A patent/HU225689B1/hu unknown
- 1996-01-24 CA CA2209301A patent/CA2209301C/en not_active Expired - Lifetime
- 1996-02-23 ZA ZA961476A patent/ZA961476B/xx unknown
1997
- 1997-08-22 FI FI973466A patent/FI121012B/fi not_active IP Right Cessation
- 1997-08-22 NO NO19973863A patent/NO321459B1/no not_active IP Right Cessation
1999
- 1999-06-15 US US09/333,636 patent/US6410014B1/en not_active Expired - Lifetime
2002
- 2002-02-25 US US10/179,778 patent/US20020176851A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO1996026265A1 (en)	1996-08-29
DK0812352T3 (da)	2006-08-21
KR19980702451A (ko)	1998-07-15
DE69636053D1 (de)	2006-05-24
NZ302090A (en)	2000-01-28
ZA961476B (en)	1997-03-06
EP0812352A4 (en)	2000-09-13
AU703125B2 (en)	1999-03-18
FI973466L (fi)	1997-08-22
DE69636053T2 (de)	2006-11-23
CZ260197A3 (cs)	1998-05-13
HUP9800459A2 (hu)	1998-06-29
AU4767596A (en)	1996-09-11
RU2225870C2 (ru)	2004-03-20
NO973863D0 (no)	1997-08-22
NZ501340A (en)	2004-12-24
NO321459B1 (no)	2006-05-15
CA2209301C (en)	2010-11-23
ES2258772T3 (es)	2006-09-01
HUP9800459A3 (en)	2001-01-29
PT812352E (pt)	2006-07-31
US20020176851A1 (en)	2002-11-28
ATE323755T1 (de)	2006-05-15
US6410014B1 (en)	2002-06-25
JPH11500621A (ja)	1999-01-19
JP4170389B2 (ja)	2008-10-22
KR100454396B1 (ko)	2005-01-17
FI121012B (fi)	2010-06-15
EP0812352A1 (en)	1997-12-17
HU225689B1 (en)	2007-06-28
CA2209301A1 (en)	1996-08-29
US5912170A (en)	1999-06-15
NO973863L (no)	1997-10-22
FI973466A0 (fi)	1997-08-22
AU703125C (en)	2004-11-25
EP0812352B1 (en)	2006-04-19

Legal Events

Date	Code	Title	Description
2000-06-30	PD00	Pending as of 2000-06-30 in czech republic
2016-02-03	MK4A	Patent expired	Effective date: 20160124

Publication	Publication Date	Title
US6410014B1 (en)	2002-06-25	Redirection of cellular immunity by protein-tyrosine kinase chimeras
US7320787B2 (en)	2008-01-22	Redirection of cellular immunity by protein tyrosine kinase chimeras
RU2167676C2 (ru)	2001-05-27	Перенаправление клеточного иммунитета посредством химерных рецепторов
CZ281881B6 (cs)	1997-03-12	Buňka, která expresí poskytuje proteinovou membránou vázaný chimeruí receptor
KR100278352B1 (ko)	2001-01-15	수용체 키메라에 의한 세포 면역성의 전환